Concepedia

Reem Ghalib

RG

Statistics

Publications

45

Citations

12.6K

H-Index

32

Active since

2000

Affiliations

Clinical Research Institute(Current)

Texas Liver Institute

The University of Texas at San Antonio Health Science Center

Gilead Sciences (United States)

University of Florida

Reem Ghalib is an author at Clinical Research Institute specializing in antiviral therapy, viral hepatitis, and pharmacotherapy.

Publications per year

2000–2023

45

Publications

45

Ledipasvir and Sofosbuvir for Previously Treated HCV Genotype 1 Infection

Nezam H. Afdhal, K. Rajender Reddy, David R. Nelson et al. · New England Journal of Medicine · 2014 · 1.3K citations

, , +12

Obeticholic acid for the treatment of non-alcoholic steatohepatitis: interim analysis from a multicentre, randomised, placebo-controlled phase 3 trial

Zobair M. Younossi, Vlad Ratziu, Rohit Loomba et al. · The Lancet · 2019 · 1.2K citations · Full text

, , +8

Peginterferon Alfa-2b or Alfa-2a with Ribavirin for Treatment of Hepatitis C Infection

John G. McHutchison, Eric Lawitz, Mitchell L. Shiffman et al. · New England Journal of Medicine · 2009 · 1.2K citations · Full text

, , +14

Ledipasvir and Sofosbuvir for 8 or 12 Weeks for Chronic HCV without Cirrhosis

Kris V. Kowdley, Stuart C. Gordon, K. Rajender Reddy et al. · New England Journal of Medicine · 2014 · 1.1K citations · Full text

, , +13

Simeprevir plus sofosbuvir, with or without ribavirin, to treat chronic infection with hepatitis C virus genotype 1 in non-responders to pegylated interferon and ribavirin and treatment-naive patients: the COSMOS randomised study

Eric Lawitz, Mark Sulkowski, Reem Ghalib et al. · The Lancet · 2014 · 818 citations

, , +16

1–5 of 45